Skip to Content


In the US, Evolocumab (evolocumab systemic) is a member of the drug class PCSK9 inhibitors and is used to treat High Cholesterol, High Cholesterol - Familial Heterozygous and High Cholesterol - Familial Homozygous.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Lipid lowering agent for the treatment of homozygous familial hypercholesterolemia

Lipid modifying agent

Chemical Name

Immunoglobulin G2-lambda, anti-[Homo sapiensPCSK9 (proprotein convertase subtilisin/kexin type 9)], Homo sapiensmonoclonal antibody;gamma2 haevy chain (1-441)[Homo sapiensVH (IGHV1-18*01 (93.90%) -(IGHD)-IGHJ6*01))[8.8.8](1-115) -IGHG2*01 (CH1 (116-213), (WHO)

Foreign Names

  • Evolocumabum (Latin)
  • Evolocumab (German)
  • √Čvolocumab (French)
  • Evolocumab (Spanish)

Generic Names

Brand Names

  • Repatha
    Amgen, Germany; Amgen, United Kingdom; Amgen, United States; Amgen Switzerland, Switzerland


ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.